A Phase I biodistribution study of 111-Indium-CMD-193 in patients with advanced tumours expressing the Lewis-Y antigen

Trial Profile

A Phase I biodistribution study of 111-Indium-CMD-193 in patients with advanced tumours expressing the Lewis-Y antigen

Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2007

At a glance

  • Drugs CMD 193 (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top